Article Text

Download PDFPDF
Cardiovascular risk in androgen suppression: underappreciated, under-researched and unresolved
  1. Liam Bourke1,
  2. Timothy J A Chico2,3,
  3. Peter C Albertsen4,
  4. Freddie C Hamdy5,
  5. Derek J Rosario6
  1. 1Department of Primary Care and Public Health, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
  2. 2NIHR Cardiovascular Biomedical Research Unit, Sheffield Teaching Hospitals NHS Foundation Trust, Herries Road, Sheffield, UK
  3. 3Department of Cardiovascular Sciences, University of Sheffield, Sheffield, UK
  4. 4Department of Surgery, University of Connecticut Health Centre, Farmington, Connecticut, USA
  5. 5Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
  6. 6Academic Urology Unit, Department of Urology, School of Medicine, University of Sheffield, Royal Hallamshire hospital, Sheffield UK
  1. Correspondence to Derek J Rosario, Academic Urology Unit, K Floor, Department of Oncology, Royal Hallamshire Hospital, Glossop Road, University of Sheffield, Sheffield S11 7FE, UK; d.j.rosario{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


Cardiovascular disease (CVD) and prostate cancer represent major public health problems. In 2009, over 180 000 people died from CVD in the UK ( Over the past 30 years, the incidence of prostate cancer has almost tripled, with much of this increase attributable to increased early detection due to widespread prostate specific antigen (PSA) testing. Although many of these cases are related to localised disease, around one-third of the 37 000 men diagnosed in the UK annually ( will have advanced prostate cancer. The mainstay of treatment for such men is androgen suppression therapy (AST). Immediate initiation of AST is well supported by proven clinical benefits for men with symptomatic skeletal metastases,1 established lymphatic metastases2 and when combined with radiotherapy in locally advanced disease.3 4 However, as a result of PSA testing, men outside these groups are now started on AST much earlier, and remain on therapy for many years. AST is associated with a number of adverse effects, such as reduced bone mineral density, increased fracture risk, decreased skeletal muscle function and fatigue.5 However, more recently attention has turned to the risk of CVD in association with AST. Although AST clearly improves prostate cancer specific mortality (RR reduction of 17%) it does so at the expense of a 15% increase in the RR of non-disease specific mortality.1 Although CVD is of course highly prevalent in the population on AST (ie, older men), evidence accruing from observational data now suggests AST may significantly increase CVD morbidity and mortality.

What is the evidence suggesting AST increases CVD risk?

Several reports have documented an increased risk of death related to CVD in men treated with AST.6 A pooled analysis of three randomised controlled trials suggests AST is …

View Full Text


  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.